Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Randomized trial of a dry-powder, fibrin sealant in vascular procedures.

Gupta N, Chetter I, Hayes P, O-Yurvati AH, Moneta GL, Shenoy S, Pribble JP, Zuckerman LA.

J Vasc Surg. 2015 Nov;62(5):1288-95. doi: 10.1016/j.jvs.2015.05.038. Epub 2015 Aug 5.

2.

Safety and efficacy of a novel, dry powder fibrin sealant for hemostasis in hepatic resection.

Ruitenbeek K, Ayez N, Verhoef C, de Wilt JH, Bottema J, Rijken AM, van Rij M, Koopman J, Zuckerman LA, Frohna P, Porte RJ.

Dig Surg. 2014;31(6):422-7. doi: 10.1159/000370006. Epub 2015 Jan 14.

PMID:
25592001
3.

Fibrocaps for surgical hemostasis: two randomized, controlled phase II trials.

Verhoef C, Singla N, Moneta G, Muir W, Rijken A, Lockstadt H, de Wilt JH, O-Yurvati A, Zuckerman LA, Frohna P, Porte RJ.

J Surg Res. 2015 Apr;194(2):679-87. doi: 10.1016/j.jss.2014.12.011. Epub 2014 Dec 10.

PMID:
25586331
4.

The FINISH-3 trial: a phase 3, international, randomized, single-blind, controlled trial of topical fibrocaps in intraoperative surgical hemostasis.

Bochicchio GV, Gupta N, Porte RJ, Renkens KL, Pattyn P, Topal B, Troisi RI, Muir W, Chetter I, Gillen DL, Zuckerman LA, Frohna PA.

J Am Coll Surg. 2015 Jan;220(1):70-81. doi: 10.1016/j.jamcollsurg.2014.09.019. Epub 2014 Oct 13.

PMID:
25458801
5.

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E.

J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81. doi: 10.1016/j.jpba.2008.09.020. Epub 2008 Sep 19. Review.

PMID:
18993008
6.

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A.

J Immunol Methods. 2008 Apr 20;333(1-2):1-9. doi: 10.1016/j.jim.2008.01.001. Epub 2008 Jan 29. Review.

PMID:
18275969
7.

Preclinical safety of recombinant human thrombin.

Heffernan JK, Ponce RA, Zuckerman LA, Volpone JP, Visich J, Giste EE, Jenkins N, Boster D, Pederson S, Knitter G, Palmer T, Wills M, Early RJ, Rogge MC.

Regul Toxicol Pharmacol. 2007 Feb;47(1):48-58. Epub 2006 Sep 12.

PMID:
16971028
8.

Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.

Visich JE, Zuckerman LA, Butine MD, Gunewardena KA, Wild R, Morton KM, Reynolds TC.

Thromb Haemost. 2005 Oct;94(4):802-7.

PMID:
16270634
9.

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA.

J Immunol Methods. 2004 Jun;289(1-2):1-16.

PMID:
15251407
10.

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

Koren E, Zuckerman LA, Mire-Sluis AR.

Curr Pharm Biotechnol. 2002 Dec;3(4):349-60. Review.

PMID:
12463417
11.

Determination of the tyrosine phosphorylation sites in the T cell transmembrane glycoprotein CD5.

Dennehy KM, Ferris WF, Veenstra H, Zuckerman LA, Killeen N, Beyers AD.

Int Immunol. 2001 Feb;13(2):149-56.

PMID:
11157848
12.

Negative regulation of CD4 lineage development and responses by CD5.

Peña-Rossi C, Zuckerman LA, Strong J, Kwan J, Ferris W, Chan S, Tarakhovsky A, Beyers AD, Killeen N.

J Immunol. 1999 Dec 15;163(12):6494-501.

13.

Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation.

Zuckerman LA, Pullen L, Miller J.

J Immunol. 1998 Apr 1;160(7):3259-68.

14.

Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies.

Lenschow DJ, Zeng Y, Hathcock KS, Zuckerman LA, Freeman G, Thistlethwaite JR, Gray GS, Hodes RJ, Bluestone JA.

Transplantation. 1995 Nov 27;60(10):1171-8.

PMID:
7482727
15.

Identification of a unique costimulatory activity for murine T helper 1 T cell clones.

Zuckerman LA, Sant AJ, Miller J.

J Immunol. 1995 May 1;154(9):4503-12.

PMID:
7536772
16.

Expression and functional significance of an additional ligand for CTLA-4.

Lenschow DJ, Su GH, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA.

Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11054-8.

17.

A comparison of life events scoring methods as predictors of psychological symptomatology.

Zuckerman LA, Oliver JM, Hollingsworth HH, Austrin HR.

J Human Stress. 1986 Summer;12(2):64-70.

PMID:
3559190

Supplemental Content

Loading ...
Support Center